Industries > Pharma > Global Anti-Epilepsy Drugs Market Forecast 2017-2027

Global Anti-Epilepsy Drugs Market Forecast 2017-2027

First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin

PUBLISHED: 12 May 2017
PAGES: 145
PRODUCT CODE: PHA0193
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0193 Categories: ,

The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 145-page report you will receive 100 charts – all unavailable elsewhere.

The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Anti-Epilepsy Drugs Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets:
– First-generation Drugs
– Second-generation Drugs
– Third-generation Drugs
– Others

Global Anti-Epilepsy Drugs Market Forecast 2017-2027

• This report also discusses the leading anti-epilepsy drugs:
– Vimpat
– Keppra
– Briviact
– Lamictal
– Potiga/Trobalt
– Lyrica
– Neurontin

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
– US
– Japan
– EU5
– BRIC
– RoW

• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK

• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market

• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy

• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market

• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.

Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Epilepsy Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Anti-Epilepsy Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

READ

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

READ

Visiongain Publishes Respiratory Drug Delivery Technologies Market Report 2022-2032

The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.

15 June 2022

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

14 June 2022

READ

Categories